Shaping the Next Era of Global Biomanufacturing: Chime Biologics Brings Its “GMP” Vision to CPHI Milan 2026

  • Advancing a genuine global dual-source strategy: Chime Biologics and Rezon Bio jointly showcased a global dual-source manufacturing model connecting capabilities across China and Europe.
  • Megafactory officially launched: Chime Biologics announced the launch of its next-generation Megafactory, designed to enable greater scale, flexibility and AI-powered biologics manufacturing.
  • Meeting the expanding global demand for biosimilars: With more than a decade of biosimilar expertise, Chime Biologics offers customizable and flexible partnership models tailored to the diverse needs of emerging biosimilar developers.

Milan, Italy | October 2026 — Global biopharmaceutical manufacturing is entering a new phase, driven by the need for more resilient supply networks, next-generation manufacturing infrastructure, and broader access to biologic medicines. At CPHI Milan 2026, Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, highlighted three strategic capabilities that reflect how the company is responding to these shifts: Genuine in Dual Source, Megafactory Redefining Biomanufacturing, and Pioneer in Biosimilar. Across the three themes, Chime Biologics showcased its continued evolution from a China-based manufacturing platform into a global biologics CDMO built to support clients across development, commercialization, and global supply.

Building a Truly Global Dual-Source Manufacturing Network

As pharmaceutical companies place greater emphasis on supply continuity and geographic resilience, dual sourcing is evolving from a contingency strategy into an important element of global manufacturing planning. At CPHI Milan, Chime Biologics and European biologics CDMO Rezon Bio jointly showcased their collaboration under Chime Biologics’ Global Dual-Source Strategy, connecting manufacturing capabilities in China and Europe to support clients with greater flexibility and supply resilience. The strategy is designed to combine the manufacturing efficiency and integrated biopharmaceutical ecosystem in China with a broader global supply network, enabling clients to address evolving commercial, regulatory and supply-chain requirements across regions. By bringing both organizations together on the international CPHI stage, Chime Biologics demonstrated what it means by “Genuine in Dual Source”: not simply having manufacturing sites in two locations, but building an interconnected manufacturing model capable of supporting global development and commercialization. Chime Biologics and Rezon Bio formally announced their strategic collaboration earlier this year, making their joint presence at CPHI another important milestone in bringing this global dual-source model to the market.

From Manufacturing Scale to Intelligent Manufacturing: Megafactory Project Officially Launched

The second major theme was Chime Biologics’ next-generation manufacturing vision. At CPHI, Chime Biologics highlighted that its Megafactory project has officially been launched, marking a major step in the company’s long-term manufacturing strategy. The project goes beyond capacity expansion. Designed as an integrated next-generation biologics manufacturing campus, the Megafactory is planned to include more than 100 sets of 2,000/5,000 L single-use bioreactors, together with supporting upstream and downstream manufacturing infrastructure and the integration of the Chime AI Platform. The objective is to create a manufacturing environment capable of responding more flexibly to different molecules, development stages, production requirements and commercial scenarios, while progressively embedding digitalization and AI into manufacturing operations. Building on Chime Biologics’ experience as an early adopter of modular biologics manufacturing, the Megafactory represents the company’s next step toward a more flexible, scalable and intelligent manufacturing model. Chime Biologics previously unveiled its broader vision of moving “From Modular Innovation to Intelligent Megafactory” as part of its next-generation global biomanufacturing strategy.

Biosimilars Enter a Broader Global Market, Calling for More Flexible Partnership Models

The conversations at CPHI also reflected growing interest in biosimilars from pharmaceutical companies across emerging markets and developing economies. As more markets seek to expand access to biologic medicines, new biosimilar developers are entering the field with diverse levels of experience, resources and commercialization strategies. For these emerging players, a standardized CDMO model may not always fit the realities of their development journey. Chime Biologics brings more than a decade of dedicated biosimilar experience, with capabilities spanning cell line development, process development, clinical supply and global commercial manufacturing. Drawing on this expertise, Chime Biologics provides flexible and tailored partnership models, including fee-for-service, milestone-based collaboration, and co-development with value-added licensing opportunities, allowing different partners to structure their programs around their specific development and commercial objectives. Throughout CPHI, Chime Biologics engaged in substantive discussions with numerous potential partners from different regions, covering product development strategies, manufacturing requirements, global supply models and commercialization plans. These conversations underscored the breadth of opportunities emerging as biosimilar development expands into more markets around the world.

Three Dimensions of a New Global Biomanufacturing Model

Together, Genuine in Dual Source, Megafactory Redefining Biomanufacturing, and Pioneer in Biosimilar represent three connected dimensions of Chime Biologics’ global strategy. The first addresses the growing need for resilient global supply; the second looks beyond conventional manufacturing scale toward a more flexible and intelligent production model; and the third builds on more than a decade of biosimilar expertise to address the evolving needs of developers around the world. For Chime Biologics, becoming global is not simply about expanding geographic reach. It is about combining global manufacturing capabilities, next-generation infrastructure and flexible partnership models to deliver solutions that are increasingly tailored to where clients are in their development and commercialization journeys. As conversations initiated at CPHI progress into new collaborations, Chime Biologics continues to build its role as a global partner for the next generation of biologics.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry and we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.

For more information, please visit www.chimebiologics.com.